BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» Santhera Licenses European Idebenone Rights To Takeda
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Santhera Licenses European Idebenone Rights To Takeda
Aug. 10, 2005
By
Cormac Sheridan
No Comments
Santhera Pharmaceuticals AG licensed to Takeda the European rights to its Friedreich's Ataxia (FRDA) treatment, idebenone, in a deal which earned it an up-front payment of EUR5 million (US$6.2 million). (BioWorld International)
BioWorld Asia